Turning Point Therapeutics: Precision Medicine Company

TP Therapeutics, Inc. (TP) is a clinical-stage structure-based drug design company for the discovery and development of precision medicines for cancer and other diseases.  We are focusing on the design of novel chemical identities for established oncogene drivers with secondary resistant mutations, newly identified disease-driven targets, and potential targets regulating tumor microenvironment and tumor immunity.  Our lead therapeutic project, TPX-0005 (Repotrectinib), is in clinical development (TRIDENT-1).  TP- Turning Point Medicines for Life!

Athena Countouriotis, M.D., Chief Executive Officer, TP Therapeutics

Dr. Countouriotis was promoted to Chief Executive Officer and named to the TP Therapeutics board of directors in September 2018. She has broad oncology biotech leadership experience, guiding multiple development programs to approval. Her experience includes large and small molecule therapeutics in hematologic and solid tumor indications, with multiple regulatory approvals in the U.S. and Europe. She joined TP Therapeutics in May 2018 as Executive Vice President and Chief Medical Officer to advance the clinical development of repotrectinib. She previously served as Senior Vice President and Chief Medical Officer for Adverum Biotechnologies, and before that as Senior Vice President, Chief Medical Officer of Halozyme Therapeutics from January 2015 to May 2017. Dr. Countouriotis also served as Chief Medical Officer of Ambit Biosciences, where she helped lead the initial public offering and was responsible for the clinical development of quizartinib until the company’s acquisition by Daiichi Sankyo in November 2014. Earlier in her career, Dr. Countouriotis led various clinical development organizations within Pfizer and Bristol-Myers Squibb for oncology therapeutics including Sutent®, Mylotarg™, Bosulif® and Sprycel®. In addition to TP Therapeutics, Dr. Countouriotis serves on the board of directors of Trovagene and NuMedii. She earned a Bachelor of Science degree from the University of California, Los Angeles, and an M.D. from Tufts University School of Medicine. She received her initial training in pediatrics at the University of California, Los Angeles, and additional training at the Fred Hutchinson Cancer Research Center in the Pediatric Hematology/Oncology Program.

J. Jean Cui, Ph.D., Scientific Founder, Chairman, and Chief Scientific Officer

Jean is a renowned oncology drug designer with more than 20 years of experience in drug discovery and project management at Big Pharma and biotech companies (Pfizer, Pharmacia/SUGEN, etc.).  Jean is the lead inventor of Pfizer’s precision oncology medicine, crizotinib, brand named XALKORI®.  She created the drug’s novel chemical scaffold based on co-crystal structure and designed the final clinical compound crizotinib.  XALKORI® was fast track approved by US Food and Drug Administration on August 26, 2011 for ALK positive late stage non-small cell lung cancer (NSCLC).  In addition to the invention of crizotinib, Jean worked on several other oncology projects, including SUTENT®.  She also created the clinical c-MET specific inhibitor PF-04217903 and designed the ALK second generation clinical compound lorlatinib (PF-06463922).  Her exceptional achievements in drug discovery and development have earned her many prestigious awards which include: the 38th National Inventor of the Year by Intellectual Property Owners’ Association (2011); Woman Worth Watching by Diversity Journal (2012); American Chemical Society Hero of Chemistry (2013); Pfizer Worldwide R&D Achievement Awards (2006 and 2012); Pfizer Innovation Award (2011); CABS K. Fong Award for Life Sciences (2013).  Her story of crizotinib invention was featured in a Wall Street Journal article titled “Drug Discovery Gets an Upgrade” on April 16, 2012.

Yishan (Peter) Li, Ph.D., M.B.A., Co-founder, Director, and Head of TP Therapeutics, Asia

Prior to his current position, Peter served as Chairman and CEO since co-founding TP Therapeutics in October 2013 until September 2018. During these 5 years, Peter oversaw operations and financing through the company growth phases of inception, drug discovery, drug development, and clinical development with the lead compound Repotrectinib in Phase 1/2 clinical study.  Prior to founding TP Therapeutics, Peter served as Executive Vice President at Epitomics, Inc., a leading antibody technology company specializing in rabbit monoclonal antibody development for reagent, diagnostics, and therapeutics (acquired by Abcam, plc in March 2012). He spent more than 9 years at Epitomics, initially as Vice President of Life Sciences, then Senior Vice President, and Executive Vice President where he successfully built the reagent business from concept to sizable operations in both U.S. (35 FTEs) and China (165 FTEs). He oversaw all aspects of this business line, which included R&D, manufacturing, QC, marketing/sales, customer services, and oversea distributor relationship. Prior to Epitomics, Peter was Vice President at Kenson Ventures, LLC. He evaluated business plans and consulted for biotech startups on business strategies, operations, marketing and business development. He has served as members of Board of Directors and observers to the Board for multiple biotech companies.

Brian L. Baker, CPA, Vice President of Finance and Administration

Brian Baker is a licensed CPA with over 21 years of progressive senior accounting and finance experience, primarily with venture-backed, biotechnology, drug discovery and development companies. He obtained “Big Four” public accounting experience during his tenure at Price Waterhouse where he was a senior assurance advisor. In addition to Price Waterhouse, Mr. Baker has held senior financial positions with Cleave Biosciences, Phenomix Corporation, and Cengent Therapeutics. He has significant fundraising experience in excess of $200 million in equity and $35 million in venture debt.  Mr. Baker earned a Master’s of Science degree in Business Administration – Information Systems from San Diego State University, and a Bachelor’s of Science degree in Business Administration – Accounting, also from San Diego State University.

John K.C. Lim, Pharm.D., Senior Vice President, Clinical Operations and Regulatory Affairs

John brings 30 years of work experience in clinical research and new drug development, principally in the oncology and biotechnology areas.  He joined TP Therapeutics after holding senior management positions at Senhwa Biosciences, Inc. and Cylene Pharmaceuticals, Inc.  John was responsible for Clinical Operations and Regulatory Affairs, for pre-clinical and clinical research, and for developing the corporate clinical plan and regulatory strategy.  Before Cylene, John worked at US Oncology Research, where he was Vice President for Research Operations.  US Oncology is the premier cancer care services company in the USA, and its network of research sites has contributed to the clinical development and approval of more than 20 new cancer agents over the past decade.  In the years before US Oncology, John held senior operational executive positions at Covance, Quintiles, Affiliated Research Centers, and Theradex.  Originally from New Zealand, John graduated from the University of Otago with a Pharmacy degree.  After completing his Doctoral degree at the University of Kentucky, he joined the faculty at the University of Otago Medical School, where he developed the University’s first Clinical Pharmacy teaching program.

Jeffrey P. Whitten, Ph.D., M.B.A., Senior Vice President of Pre-Clinical Development

Jeffrey has worked in many different executive roles in his 30 years within the pharmaceutical and biotechnology industries. This started with his experience at Sandoz (now Novartis) and Glaxo in the UK where he worked on Salbutamol (Ventolin®), the first selective beta agonist for respiratory disease. He then came to the United States and worked for Marion Merrell Dow in their oncology and immunology programs. This included the first clinical compound as an aromatase inhibitor for breast cancer and cumulated with his work on Allegra®, a non-sedating antihistamine. Jeff then joined the biotechnology arena in San Diego where he has discovered and developed multiple innovative small molecule drug candidate’s that are currently in clinical trials around the world for auto-immune diseases and cancer. This includes Quarfloxin for solid tumors, the kinase inhibitor CX-4945 for liquid tumors, CX-5461 as an oncology pol. II inhibitor, CM-2489 for psoriasis and CM-4621 for pancreatitis. He has a BSc, PhD and Post-Doctoral fellowship from Manchester and Oxford Universities and a M.B.A. from The Ohio State University.

Armin Graber, Ph.D., Vice President of Companion Diagnostics and Biomarkers

Armin has held various executive positions in both academia and the biotechnology, pharmaceutical and diagnostics industries in Europe and the US. He brings 30 years of work experience in translational research, correlative sciences and diagnostic development, mainly in the Oncology therapeutic area. Most recently, Armin was VP, Head of Research & Product Development and Medical Affairs at Genoptix. Previously, he held various global Companion Diagnostics, Correlative Sciences and Translational Medicine positions at Novartis, was VP for Translational Research at BG Medicine, CEO of Biocrates Life Sciences, and Chair of the Department of Biomedical Sciences and Engineering and CEO of the University for Health Sciences, Medical Informatics and Technology (UMIT). Originally from Austria, Armin received a Master of Science degree in Technical Mathematics and Computer Science from the Technical University of Graz, a doctorate degree (Ph.D.) in Medical Informatics and Biostatistics from the University of Innsbruck, and a Priv.-Doz. in Bioinformatics and Translational Research from the UMIT.

Naresh K. Nayyar, Ph.D., M.B.A., RAC, Vice President of Regulatory Affairs

Dr. Naresh K. Nayyar joined TP Therapeutics in June 2018 as Vice President of Regulatory Affairs. Prior to joining TP Therapeutics, he was the Associate Vice President of Regulatory Affairs and Quality Assurance at aTyr Pharma (April 2016 to May 2018) where he was responsible for the corporate regulatory and QA functions. Preceding his experience at aTyr, he has more than 20 years of industry experience at companies such as Pfizer (1996-2009), Spectrum (2009-2010), and Halozyme (2010-2016) leading and implementing strategic regulatory paths (nonclinical, clinical, and CMC) and obtaining worldwide approvals for products such as Herceptin® SC, MabThera® SC, Rituxan Hycela® and HyQvia, as well as development strategies for numerous Phase 1-3 molecules, Phase 4 life-cycle management (namely Fusilev®, Zevalin® and Hylenex), and companion diagnostics (study risk determinations, IDE approvals, and PMA). He has also led the approval of several orphan drugs and fast track designations from US FDA and EMA. He has also participated in due diligence activities of many high-value partnerships/collaborations at Pfizer and Halozyme. Dr. Nayyar received his Ph.D. in organic chemistry from the Delhi University (India), MBA from University of Phoenix (USA) and is RAC certified.

Miriam Cruz, Vice President of Clinical Operations

Miriam joined TP Therapeutics in June 2018 as VP, Clinical Operations and is responsible for the strategic and tactical development of the clinical operations function, creating value for the organization and providing insights to business objectives and growth strategy. Miriam’s experience includes 19 years in positions of increasing responsibility within the pharmaceutical and biotech industry. Prior to joining TP Therapeutics, Miriam led the Ph1b/2 EBV+ lymphoma trial and clinical operations function at Viracta Therapeutics as VP Clinical Operations. Miriam also led the pivotal Global Phase 3 PDA trial for Halozyme Therapeutics and has experience with trial management from study initiation through study completion/primary data analysis and in multiple phases of clinical development. Miriam also held senior positions at Eisai, Merck and Schering Plough and earned her Biology degree from CCNY. Miriam is an active member of ASCO and ESMO and truly recognizes the importance of working directly with physicians and patients to address patient unmet needs.

Yuelie Lu, Ph.D., Vice President of CMC Operations

Dr. Yuelie Lu joined TP Therapeutics in July 2018 as Vice President of CMC Operations and oversee the process development and manufacturing of drug substance and drug product, analytical development, and regulatory CMC for clinical trial material supplies. Yuelie has worked in many various leadership roles in his 25 years within pharmaceutical and biotech industry including Schering-Plough (now Merck), Amgen, Lexicon Pharmaceuticals, Pharmacyclics (now part of AbbVie), and Portola Pharmaceuticals. Prior to joining TP Therapeutics, Yuelie led his teams to contribute successful launch and commercialization of IMBRUVICA® (ibrutinib), a Bruton’s tyrosine kinase (BTK) inhibitor and Breakthrough Therapy designation, at Pharmacyclics and Bevyxxa® (betrixaban), a Factor Xa inhibitor and fast track designation, at Portola. Yuelie also has extensive process development experiences for numerous Phase 1-3 small molecules including Portola’s cerdulatinib a Syk/JAK inhibitor for the treatment of hematologic cancers, Lexicon’s Telotristat Etiprate™ (Carcinoid Syndrome) and Sotagliflozin™ (Type I/II Diabetes indication)), and Amgen’s Motesanib Diphosphate® (oncology indication). Dr. Lu received his Ph.D. in organic chemistry from Purdue University.

J. Jean Cui, Ph.D.

Founder, Chairman, and Chief Scientific Officer

Please see Senior Management section for Dr. Cui’s background.

Robert Adelman, M.D., Managing Partner, VenBio Partners

Dr. Adelman has a 30+ year history of founding, investing in, and managing companies in the life sciences sector. Dr. Adelman received his undergraduate degree from University of California at Berkeley, his medical degree from Yale University, performed his residency at Cornell University Medical Center, and practiced surgery in New York and New Jersey. Before founding venBio, Dr. Adelman had a seven-year tenure as a Private Equity Partner at OrbiMed Advisors. There he was part of a team that invested $1.1B in both private and public companies across multiple venture capital funds. Dr. Adelman has co-founded a number of biotechnology companies. Dr. Adelman led Fund I’s investments into Aragon Pharmaceuticals (acquired by Johnson and Johnson) and Seragon Pharmaceutical (acquired by Genentech/Roche). Dr. Adelman is a member of the Board of Solstice Biologics, Metacrine, Alexo Therapeutics, Precision Biosciences, and Apellis.

Carl Gordon, Ph.D., CFA

Partner, OrbiMed Advisors, LLC

Carl L. Gordon, Ph.D., CFA, is a founding Partner and Co-Head of Global Private Equity at OrbiMed.  He was a senior biotechnology analyst at Mehta and Isaly from 1995 to 1997.  He was a Fellow at The Rockefeller University from 1993 to 1995.  Carl received a Ph.D. in Molecular Biology from the Massachusetts Institute of Technology (1993) and a Bachelor of Arts Degree from Harvard College (1987).  Carl was included on the Forbes Midas List of top venture capital investors in 2014.

Hongbo Lu, Ph.D., M.B.A.

Partner, Lilly Asia Ventures

Dr. Hongbo Lu is a Partner at Lilly Asia Ventures (LAV).  Previously, Hongbo was with OrbiMed Advisors, serving as its Managing Director in Asia.  Hongbo has over 15 years of investment and operational experience in healthcare industry in the US and in China, including her tenures at OrbiMed, Piper Jaffray & Co. and Zyomyx.  Hongbo received a Ph.D. in BioEngineering from the University of Washington, an M.B.A. from the Haas School of Business at the University of California, Berkeley, and graduated with honor from Tsinghua University in China.

Simeon George, M.D., M.B.A.

Partner, S.R. One, Limited

Dr. Simeon George joined SR One in 2007 and leads SR One’s investment activities on the West Coast.  Simeon is a director of Crispr Therapeutics (CRSP), eFFECTOR Therapeutics, Principia Biopharma, Progyny, and Birdrock.  Simeon previously was a director of Genocea (GNCA), HTG Molecular (HTGM) and Semprus Biosciences (acquired by Teleflex).  Prior to joining SR One, Simeon was a consultant at Bain & Company and an investment banker at Goldman Sachs and Merrill Lynch.  Simeon received his B.A. in neuroscience from the Johns Hopkins University, where he graduated Phi Beta Kappa.  Simeon received his M.D. from the University of Pennsylvania School of Medicine and his M.B.A. (Mayer Scholar) from the University of Pennsylvania Wharton School.

Kenneth Fong, Ph.D.

Chairman, Kenson Ventures, LLC

Dr. Fong is the Chairman of Kenson Ventures, LLC. Kenson specializes in venture financing and strategic consulting to biotech companies. As of January 2003, Kenson has 18 investments that mostly fall into 3 major categories: a) Innovative Research Tools, b) Platform Technologies, and c) Drug Development. Prior to founding Kenson, Dr. Fong was the founder and CEO of CLONTECH Laboratories, that was acquired by Becton Dickinson (BD) in late 1999. CLONTECH was the leader in the Molecular/Cell Biology market and in the last 4 years before its acquisition, the company had experienced an average growth rate of 36% a year. The company also had 48 consecutive quarters of double-digit growth and profits. In 1994, 1995, 1998, and 1999, CLONTECH was selected as one of the fastest-growing companies in the San Francisco Bay Area. Dr. Fong’s past experience is best suited to young companies and to those that desire to grow more rapidly. He is also adept at crafting development strategy and realistic implementation plans to promote the long-term growth of a company. Under Dr. Fong’s leadership, companies that either were acquired or went public between 2007 and 2010 are: Epitomics (to Abcam); SA Biosciences (to Qiagen); DHI (to Quidel); Fermentas (to ThermoFisher); Panomics (to Affymetrix); Bioform (IPO); and Optimer (IPO). Dr. Fong obtained his Ph.D. from Indiana University. Currently, Dr. Fong sits on the board of several companies in addition to TP Therapeutics:  Apexigen Biopharm (Burlingame), Genewiz (New Jersey), GB HealthWatch (San Diego), System Biosciences (Mountain View)  and on the Advisory Board of  Advanced Cell Diagnostics (ACD, Hayward).

Y. Peter Li, Ph.D., M.B.A.

Co-founder, Director, and Head of TP Therapeutics, Asia

Please see Senior Management section for Dr. Li’s background.

Sheila Gujrathi, M.D.

Co-Founder, President and CEO, Gossamer Bio

Dr. Sheila Gujrathi is co-founder, President, and COO of Gossamer Bio, a new biopharmaceutical company focused on the discovery and development of novel and differentiated therapeutic products to address high unmet needs of targeted patient populations in immunology, inflammation, fibrosis and oncology. Prior to that, she most recently served as Chief Medical Officer of Receptos, an immunology-focused biotechnology company that was acquired by Celgene in August 2015 for $7.2 billion. At Receptos, she built the clinical development organization and advanced the pipeline of drug candidates, including Phase 3 programs in multiple sclerosis and ulcerative colitis. Previously, Dr. Gujrathi was Vice President of the Global Clinical Development Group in Immunology at Bristol-Myers Squibb (BMS). There she led late-stage clinical development and supported regulatory filings for Orencia® and Nulojix®. She was also responsible for development of other assets in the BMS immunology clinical pipeline, and advised the strategies for discovery, early development and external business development within the immunoscience franchise. Prior to BMS, Dr. Gujrathi held roles in the immunology, tissue growth and repair clinical development groups at Genentech and served as the Avastin franchise team leader. Earlier in her career, she was also a management consultant in McKinsey & Company’s healthcare practice.
Dr. Gujrathi received her B.S. in Biomedical Engineering with Highest Distinction and M.D. from Northwestern University in the accelerated Honors Program in Medical Education. She completed her internal medicine internship and residency at Brigham and Women’s Hospital, Harvard Medical School, and additional fellowship training in Allergy/Immunology at UCSF and Stanford. She currently serves on the Board of Directors at Five Prime Therapeutics and previously served as a Director for Ambrx, which was acquired in June 2015.

Jacob Chacko, M.D., Chief Executive Officer of ORIC Pharmaceuticals

Dr. Chacko is the CEO of ORIC Pharmaceuticals, a clinical-stage oncology company focused on discovery and development of novel therapies against treatment-resistant cancers. He was previously chief financial officer of Ignyta, a NASDAQ-listed precision oncology company acquired by Roche for $1.7 billion. Prior to Ignyta, Dr. Chacko was an investor at TPG Capital where he helped lead teams that completed acquisitions having an aggregate value of over $10 billion.

He has served on the board of directors of Bonti, RentPath and EnvisionRx and was a board observer to Par Pharmaceutical, IMS Health and Quintiles Transnational. In addition, he previously served on the board of the Packard Children’s Health Alliance at the Lucile Packard Children’s Hospital Stanford. He currently chairs the Western Regional Selection Committee for the Marshall Scholarship.

Dr. Chacko concurrently received his M.D. with AOA honors from UCLA and his M.B.A. with Distinction from Harvard Business School. Prior to that, he was a consultant serving healthcare clients at McKinsey & Company. He received a M.Sc. from Oxford University as a Marshall Scholar and undergraduate degrees from the University of Southern California, where he graduated as the University Valedictorian.

Athena Countouriotis, M.D., Chief Executive Officer, TP Therapeutics

Please see Senior Management section for Athena Countouriotis’ background.

In Memoriam: Lewis (Lew) Shuster, M.B.A.

CEO, Shuster Capital

In 2002, Mr. Shuster founded Shuster Capital, a strategic and operating advisor to and angel investor in life science companies, and has served as its CEO since that time.  From June 2003 to November 2007, Mr. Shuster served as CEO of Kemia, Inc., a drug discovery and development company.  From February 2000 to December 2001, Mr. Shuster held various operating executive positions at Invitrogen Corporation.  Between 1994 and 1999, Mr. Shuster served as CFO and other executive positions at Pharmacopeia, Inc.  Mr. Shuster joined Human Genome Sciences, Inc. as its first employee in September 1992 and served as its EVP, operations and finance until 1994.  Since May 2014 Mr. Shuster has served as Board Audit Committee Chairman for HTG Molecular Diagnostics (NASDAQ: HTGM).  Mr. Shuster served as a member of the board of directors for Response Biomedical Corporation, Complete Genomics, Mast Therapeutics, Inc.  Mr. Shuster received a B.A. in Economics from Swarthmore College and an M.B.A. from Stanford University.

Daniel D. Von Hoff, M.D., FACP, FASCO, FAACR

Daniel D. Von Hoff, M.D., FACP, FASCO, FAACR, is currently Physician in Chief and Director of Translational Research at TGen (Translational Genomics Research Institute) in Phoenix, Arizona. He is also Chief Scientific Officer for US Oncology and for HonorHealth’s Clinical Research Institute.   He is also a Clinical Professor of Medicine, University of Arizona.

Dr. Von Hoff graduated from Carroll College and received his medical degree from Columbia University College of Physicians and Surgeons. He went on to complete his internship and residency in internal medicine at the University of California, San Francisco, and a fellowship in medical oncology at the National Cancer Institute. Von Hoff became a professor in the departments of medicine and cellular and structural biology at the University of Texas Health Science Center, San Antonio. In 1989, he became the founding director of the Institute for Drug Development at the Cancer Therapy and Research Center in San Antonio and 10 years later he became the director of the cancer center and professor of medicine at the University of Arizona.

Dr. Von Hoff’s major interest is in the development of new anticancer agents, both in the clinic and in the laboratory.  He and his colleagues were involved in the beginning of the development of many of the agents we now use routinely, including:  mitoxantrone, fludarabine, paclitaxel, docetaxel, gemcitabine, irinotecan, nelarabine, capecitabine, lapatinib and others.  At present, he and his colleagues are concentrating on the development of molecularly targeted therapies for patients with pancreatic and other advanced cancers.

Dr. Von Hoff has published more than 648 papers, 138 book chapters and over 1085 abstracts.  Dr. Von Hoff received the 2010 David A. Karnofsky Memorial Award from the American Society of Clinical Oncology for his outstanding contributions to cancer research leading to significant improvement in patient care.

Dr. Von Hoff was appointed to President Bush’s National Cancer Advisory Board in 2004-2010. Dr. Von Hoff is the past President of the American Association for Cancer Research (the world’s largest cancer research organization), a Fellow of the American College of Physicians, and a member and past board member of the American Society of Clinical Oncology.  Dr. Von Hoff is founder and the Editor Emeritus of Investigational New Drugs – The Journal of New Anticancer Agents; and, past Editor-in-Chief of Molecular Cancer Therapeutics. He is a co-founder of the AACR/ASCO Methods in Clinical Cancer Research Workshop.   He is also proud to have been a mentor and teacher for multiple medical students, medical oncology fellows, graduate students, and post-doctoral fellows.

Sai-Hong Ignatius Ou, M.D., Ph.D.

Dr. Sai-Hong Ignatius Ou completed his MD and PhD degrees at the University of Texas Southwestern Medical Center in Dallas, Texas; his internal medicine residency training at Duke University Medical Center, Durham, North Carolina; and his hematology-oncology fellowship training at Beth Israel Deaconess Medical Center, Harvard Medical School in Boston, Massachusetts. Dr. Ou is board-certified in Internal Medicine and Medical Oncology by the American Board of Internal Medicine. Dr. Ou joined the University of California Irvine School of Medicine immediately after completing his fellowship as an assistant clinical professor of medicine in 2003 and has been promoted to health science clinical professor of medicine in 2015. He has published about 110 peer-reviewed manuscripts in journals including New England Journal of Medicine, Lancet Oncology, Journal of Clinical Oncology, Cancer Discovery, Nature Medicine, and JAMA Oncology primarily in the field in targeted therapy in lung cancer including resistance mechanisms and the prognostic and predictive significance of smoking status and ethnicity in the outcome of lung cancer. In particular, Dr. Ou is one of the seven original principal investigators for the still ongoing phase I crizotinib trial that has led to the approval of crizotinib for the treatment of anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC). Recently, the activity of crizotinib in ROS1-rearranged NSCLC has been reported in New England Journal of Medicine in which Dr. Ou is co-first author. Currently Dr. Ou is involved in many early phase clinical trials involving novel and second-generation tyrosine kinase inhibitors in NSCLC driven by receptor tyrosine kinase rearrangement or mutations including as the lead author of of a global phase 2 study of a second generation ALK inhibitor, alectinib. Dr. Ou is also involved in the clinical trial of immunotherapy in numerous tumor types including squamous and non-squamous NSCLC. Dr. Ou is on the editorial board of Critical Reviews in Oncology/Hematology, Annals of Oncology, Clinical Lung Cancer, and Translational Lung Cancer Research. Dr. Ou is a scientific program committee member for the metastatic NSCLC track for the American Society of Clinical Oncology (ASCO) annual meeting from 2016 to 2018. Finally, Dr. Ou has been voted as one of America’s Best Doctors five years in a row since 2009.